Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 5
- Registration Number
- NCT02920359
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 680
- Registration Number
- NCT02914158
- Locations
- 🇨🇳
Guangdong People's Hospital, Guangzhou, China
🇨🇳Guangzhou First Municipal People's Hospital, Guangzhou, China
🇨🇳Maoming People's Hospital, Maoming, China
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 118
- Registration Number
- NCT02903368
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of California, San Diego Moores Cancer Center, La Jolla, California, United States
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT02778919
AASUR in High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT02772588
- Locations
- 🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Pharmatech
- Target Recruit Count
- 41
- Registration Number
- NCT02749825
- Locations
- 🇺🇸
Jazrawi-Atallah, P.C., Brooklyn, New York, United States
🇺🇸Albemarle Urology Clinic, PA, Albemarle, North Carolina, United States
🇺🇸Raj P. Chopra MD, PC, Bloomsburg, Pennsylvania, United States
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT02663908
- Locations
- 🇸🇰
Fakultna nemocnica Nitra, Nitra, Slovakia
🇺🇸Erlanger Health System, Chattanooga, Tennessee, United States
🇨🇦J. Giddens Medicine Professional Corporation, Brampton, Ontario, Canada
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 281
- Registration Number
- NCT02655237
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
- Conditions
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 76
- Registration Number
- NCT02543255
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 11
- Registration Number
- NCT02508636
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.